CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia

Summary

This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with severe aplastic anemia

Timeline

Start

2024-10-20

Primary completion

2027-10-20

Completion

2027-10-20

Drugs

Indications